# US 2020/0392182 A1 · Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392182 A1
- Document ID: US20200392182A1
- Status: Published application
- Kind: A1
- Application number: 17/003,940
- Filed: 2020-08-26
- Published: 2020-12-17
- Earliest claimed: 2016-02-04
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Jun Liu; Jingxin Wang; Zhaoli Sun; Sam Hong
- Web page: https://patentgrep.com/patent/US20200392182A1

## CPC

- A61P 27/02: Ophthalmic agents
- C07K 5/1008: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0031: {Rectum, anus}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 38/07: Tetrapeptides
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/10: for impotence
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 27/04: Artificial tears; Irrigation solutions
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 498/18: Bridged systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A compound of Formula I, and its analogs are provided. Compositions that include Formula I can be used to inhibit human equilibrative nucleoside transporter 1, increase adenosine signaling and produce effects that include increasing antiviral activity, increasing antiparasitic activity, increasing alcohol tolerance, decreasing pain protecting from ischemia as well as many other conditions.

## Claims

### Claim 1

A compound with the following formula:
wherein
n is an integer selected from 0 to 6;
R1 is selected from the group consisting of
when R1 is
each R1′, R2′, R3′, R4′, and R5′ is independently selected from the group consisting of OH, NH2, SH, CN, H, OAc, and OMe,
when R1 is
each A, B, X, Y, and Z is independently C or N,
when R1 is
each R1′, R2′, R3′, R4′, and R5′ is independently selected from the group consisting of OH, NH2, SH, H, OAc, and OMe,
when R1 is
each A, X, Y, and Z is independently selected from the group consisting of —(CH)m-, O, N, and S, m is an integer selected from 0 to 2;
each R2, R3, and R4 is independently selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, phenyl, OH, NH2, SH, and CN;
each R5, R6, R7, and R8 is independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, phenyl, OH, NH2, SH, and CN;
each R9 and R10 is independently selected from the group consisting of OH, NH2, SH, CN, and hydrogen;
each R11, R12, R13, and R14 is independently selected from the group consisting of hydrogen and methyl;
each R15 and R16 is independently selected from the group consisting of OH, NH2, SH, CN and hydrogen;
“” represents a single bond or a double bond with E or Z configuration; and
the amino acids with residues 1 to 4 are selected from the group consisting of
or residue 1, 2, 3, or 4 and the adjacent nitrogen form

### Claim 2 (depends on 1)

A method of inhibiting human equilibrative nucleoside transporter 1 (ENT1) comprising administering to a subject in need thereof an effective amount of the compound of claim 1, thereby inhibiting ENT1.

### Claim 3 (depends on 1)

A method of increasing adenosine signaling comprising administering to a subject in need thereof an effective amount of the compound of claim 1, thereby increasing adenosine signaling.

### Claim 4 (depends on 3)

The method according to claim 3, wherein administering the compound results in one or more of the effects selected from the group consisting of an increase in antiviral activity, an increase in antiparasitic activity, an increase in alcohol tolerance, a decrease in pain, protection from ischemia, attenuation of epileptic seizure severity, lessening of erectile dysfunction, improvement of liver function, improvement of respiratory disorders, improvement of sepsis, improvement of thrombosis, improvement of hypertension, improvement of inflammatory disorders, improvement of allergies, improvement of cardiac ischemias, improvement of arrhythmias, improvement of Parkinson's disease, improvement of chronic heart failure, improvement of rheumatoid arthritis, improvement of dry eye disease, improvement of chronic plaque type psoriasis, improvement of chronic neuropathological pain, and improvement of sickle cell disease.

### Claim 5 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein the composition is in a dosage form suitable for oral administration, rectal administration, percutaneous administration or parenteral injection.
